Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia
- Registration Number
- NCT04709224
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Brief Summary
This is an open-label study to determine the pharmacokinetics, safety and tolerability of single ascending doses of lumateperone long-acting injectable formulation in patients with schizophrenia. Patients will be enrolled in one of up to four cohorts. All patients will receive oral lumateperone for 5 days, followed by a 5-day washout of oral lumateperone, then followed by a single dose of lumateperone LAI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
- Male or female patients aged 18 to 50 years, inclusive
- Clinical diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
- Clinically stable and free from acute exacerbation of psychosis for at least 3 months prior to Screening per Investigator assessment
- On a stable dose of antipsychotic medication, including lumateperone, for at least 3 months prior to the Screening Visit
- Clinical Global Impression - Severity (CGI-S) score ≤ 3
Key
Read More
Exclusion Criteria
- Clinically significant abnormality within 2 years of Screening that, in the Investigator's opinion, may place the patient at risk or interfere with study outcome variables
- History of psychiatric condition other than schizophrenia that, in the Investigator's opinion, may be detrimental to participation in the study
- Any suicidal ideation within the 6 months prior to Screening, any suicidal behavior within 2 years prior to Screening based on the Columbia-Suicide Severity Rating Scale (C-SSRS) (excluding self-injurious, non-suicidal behavior), and/or Investigator assessment that the patient is a safety risk to him/herself or others
- Surgical or medical condition (active or chronic) that in the Investigator's opinion may interfere with drug absorption, distribution, metabolism, or excretion of the study drug or any other condition that may place the patient at risk; history of gastric bypass or sleeve gastrectomy; history of severe dystonic reaction on antipsychotics such as laryngeal spasm
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohort 1: LAI Lumateperone 50 mg SC in the abdomen Lumateperone Long-Acting Injectable - Cohort 3: LAI Lumateperone 200 mg SC in the abdomen Lumateperone Long-Acting Injectable - Cohort 2: LAI Lumateperone 100 mg SC in the abdomen Lumateperone Long-Acting Injectable - Cohort 4: LAI Lumateperone 100 or 200 mg SC in the outer area of the upper arm Lumateperone Long-Acting Injectable -
- Primary Outcome Measures
Name Time Method Pharmacokinetics: Terminal elimination half-life (T1/2) of lumateperone and metabolites predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of lumateperone and metabolites predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Time of maximum observed plasma concentration (Tmax) of lumateperone and metabolites predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Area under the plasma concentration-time curve (AUC0-t,SR) of lumateperone and metabolites during sustained-release phase predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf) of lumateperone and metabolites predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Maximum observed plasma concentration (Cmax) of lumateperone and metabolites predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Maximum observed plasma concentration (Cmax,BR) of lumateperone and metabolites during burst-release phase predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Time of maximum observed plasma concentration (Tmax,BR) of lumateperone and metabolites during burst-release phase predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Area under the plasma concentration-time curve (AUC0-t,BR) of lumateperone and metabolites during burst-release phase predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Maximum observed plasma concentration (Cmax,SR) of lumateperone and metabolites during sustained-release phase predose and at multiple timepoints up to 7 weeks postdose Pharmacokinetics: Time of maximum observed plasma concentration (Tmax,SR) of lumateperone and metabolites during sustained-release phase predose and at multiple timepoints up to 7 weeks postdose
- Secondary Outcome Measures
Name Time Method Change from baseline in Systolic and Diastolic Blood Pressure up to 7 weeks postdose Change from baseline in white blood cell count up to 7 weeks postdose Change from baseline in alanine aminotransferase up to 7 weeks postdose Change from baseline in hemoglobin up to 7 weeks postdose Change from baseline in aspartate aminotransferase up to 7 weeks postdose Percentage of participants with treatment-emergent AEs up to 7 weeks postdose Change from baseline in platelet count up to 7 weeks postdose Change from baseline in creatine kinase up to 7 weeks postdose Change from baseline in Abnormal Involuntary Movement Scale up to 7 weeks postdose AIMS is a measure of facial and oral movements, extremity movements and trunk movements. Items are rated on a scale from none (0) to severe (4).
Change from baseline in glucose up to 7 weeks postdose Change from baseline in ECG QT Interval up to 7 weeks postdose
Trial Locations
- Locations (1)
Clinical Site
🇺🇸Marlton, New Jersey, United States